An interventional study of tDCS (active) and Attention-focused sentence comprehension treatment in Aphasia Following Cerebral Infarction, Stroke Ischemic and Fatigue Symptom, sponsored by Syracuse University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Syracuse University · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to determine if electrical brain stimulation applied to the front parts of the brain can help people who have had a stroke improve their fatigue, language, and attention. The main question it aims to answer is:
Researchers will compare active electrical stimulation to sham stimulation to see if the active stimulation does a better job at reducing fatigue and language deficits after stroke. Participants will be asked to complete fatigue, language, and cognitive testing before and after receiving 10 sessions of tDCS plus speech and language therapy.
2,612 studies on the registry are indexed under Ischemic Stroke; 971 are open to participants now.
This study's planned enrollment of 60 is below the median of 120 across 1,776 interventional studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →Syracuse University is the lead sponsor of 33 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
active tDCS and attention focused language treatment will be administered
Device: tDCS (active) · Behavioral: Attention-focused sentence comprehension treatment
active tDCS and sentence picture matching treatment will be administered
Device: tDCS (active) · Behavioral: Sentence comprehension treatment
sham tDCS and attention focused language treatment will be administered
Behavioral: Attention-focused sentence comprehension treatment · Device: tDCS (sham)
sham tDCS and sentence picture matching treatment will be administered
Behavioral: Sentence comprehension treatment · Device: tDCS (sham)
The investigators will administer active tDCS to left dorsolateral prefrontal cortex (DLPFC) during 10 sessions of behavioral treatment. For active tDCS, the current will slowly be increased to 2mA and applied for 20 minutes.
Also known as: transcranial direct current stimulation
This is a specific type of speech-language therapy that focuses on simultaneously improving auditory comprehension and behavioral attention. Participants will receive 10 sessions of this treatment.
This is a specific type of speech-language therapy that focuses on improving auditory comprehension . Participants will receive 10 sessions of this treatment.
The investigators will administer sham tDCS to left dorsolateral prefrontal cortex (DLPFC) during 10 sessions of behavioral treatment. For sham tDCS, the current will slowly be increased to 2mA over the course of 30 seconds and then immediately ramped back down to zero.
Also known as: transcranial direct current stimulation
Fatigue Interference and Severity Scale for Aphasia (FISS-A)
Scale from 1-7, higher scores mean more significant fatigue
Time frame: baseline; within 1 week following the final treatment session; 3- month follow-up
Continuous Performance Test (CPT)
Time frame: baseline; within 1 week following the final treatment session; 3- month follow-up
Attention Network Test (ANT)
Time frame: baseline; within 1 week following the final treatment session; 3- month follow-up
Sentence comprehension task
Time frame: baseline; within 1 week following the final treatment session; 3- month follow-up
Plan to share: Yes — Data generated for this project will include participant demographic data, medical information related to the participant's stroke (e.g., date of stroke onset, lesion location), standardized test scores from language and cognitive tests (e.g., Western Aphasia Battery), and outcome measure data. All data will be de-identified.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Shared data and supporting information generated from this project will be made available as soon as possible, and no later than one year following the end of the funding period (11/30/2029). The duration of preservation and sharing of the data will be a minimum of 6 years after the end of the funding period.
Access criteria: Controlled access will not be used. The data that is shared will be shared by unrestricted download. All datasets that can be shared will be deposited in Open Science Framework. Open Science Framework provides searchable study-level metadata for dataset discovery. Open Science Framework assigns DOIs as persistent identifiers and has a robust preservation plan to ensure long-term access. Data will be discoverable online through standard web search of the study-level metadata as well as the persistent pointer from the DOI to the dataset.
Data sharing details ↗ · doi.org
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Sep 2029, 49 months after the start.
Of 572 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 49 months is above that.
Counting every sponsor, half of 653 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Syracuse University